Globus Medical, Inc. $GMED Shares Bought by Corient Private Wealth LP

Key Points

• Corient Private Wealth increased its Globus Medical stake by 17.5% in the second quarter to 216,853 shares, while institutional investors and hedge funds collectively own 95.16% of the company.
• Globus Medical exceeded quarterly expectations, reporting $1.34 in EPS versus the $1.10 consensus and $789.61 million in revenue, up 5.9% year over year. The company reaffirmed fiscal 2026 EPS guidance of $4.95–$5.05.
• Analyst sentiment remains positive, with a consensus rating of “Moderate Buy” and an average price target of $101.77, although several firms recently lowered their targets. Shares recently traded at $75.70, while a company director sold 25,000 shares at $87.04.

Corient Private Wealth LP grew its holdings in Globus Medical, Inc. (NYSE:GMED - Free Report) by 17.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 216,853 shares of the medical device company's stock after buying an additional 32,343 shares during the quarter. Corient Private Wealth LP owned 0.16% of Globus Medical worth $17,134,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. California State Teachers Retirement System grew its position in shares of Globus Medical by 7,827.7% in the second quarter. California State Teachers Retirement System now owns 10,326,607 shares of the medical device company's stock valued at $815,905,000 after purchasing an additional 10,196,347 shares in the last quarter. Norges Bank purchased a new position in Globus Medical during the fourth quarter worth approximately $89,922,000. Paradigm Capital Management Inc. NY purchased a new position in Globus Medical during the second quarter worth approximately $70,042,000. Northwestern Mutual Wealth Management Co. boosted its stake in Globus Medical by 71,618.6% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 716,469 shares of the medical device company's stock worth $62,555,000 after buying an additional 715,470 shares during the last quarter. Finally, American Capital Management Inc. acquired a new position in Globus Medical during the second quarter worth $51,599,000. 95.16% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Globus Medical

In other Globus Medical news, Director Stephen Zarrilli sold 25,000 shares of the company's stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the transaction, the director directly owned 25,000 shares in the company, valued at $2,176,000. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 18.38% of the stock is currently owned by insiders.

Globus Medical Price Performance

Shares of GMED stock opened at $75.70 on Tuesday. Globus Medical, Inc. has a 1-year low of $54.15 and a 1-year high of $101.40. The firm has a market cap of $10.16 billion, a PE ratio of 19.36, a price-to-earnings-growth ratio of 1.19 and a beta of 0.95. The company has a 50-day moving average of $80.31 and a two-hundred day moving average of $83.64.

Globus Medical (NYSE:GMED - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.10 by $0.24. The business had revenue of $789.61 million for the quarter, compared to the consensus estimate of $782.88 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The business's revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.86 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Sell-side analysts anticipate that Globus Medical, Inc. will post 4.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Royal Bank Of Canada cut their target price on Globus Medical from $120.00 to $115.00 and set an "outperform" rating for the company in a research note on Monday, July 13th. UBS Group initiated coverage on shares of Globus Medical in a research report on Tuesday, July 28th. They set a "neutral" rating and a $82.00 price target on the stock. Truist Financial dropped their price objective on shares of Globus Medical from $115.00 to $100.00 and set a "buy" rating for the company in a report on Thursday, July 16th. Zacks Research upgraded shares of Globus Medical from a "hold" rating to a "strong-buy" rating in a research report on Monday, August 10th. Finally, Wells Fargo & Company decreased their target price on shares of Globus Medical from $103.00 to $99.00 and set an "overweight" rating on the stock in a report on Friday, August 7th. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $101.77.

Globus Medical Company Profile

Globus Medical, Inc NYSE: GMED is a medical device company that develops, manufactures and markets musculoskeletal solutions for surgeons, hospitals and patients. Its primary focus is spinal surgery, supported by a portfolio of implants, instruments and enabling technologies designed to assist with procedures involving the cervical, thoracic and lumbar spine.

The company's products include spinal fusion systems, interbody devices, deformity correction systems, biologics and surgical instruments.

Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical, Inc. (NYSE:GMED - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.